

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

Ranbaxy Q1 FY 2015 (Apr'14-Jun'14) Sales Rs.23.7 Bn

Growth registered in Base business profitability

TOKYO, Japan (July 31, 2014) – Attached is a press release from Ranbaxy Laboratories Ltd., a subsidiary of Daiichi Sankyo Co., Ltd., detailing a correction to the release which was issued on July 29, 2014.

July 30, 2014

TO: **STOCK EXCHANGES**

Dear Sirs,

Sub: Press Release dated July 29, 2014 titled “Ranbaxy Q1 FY 2015 (Apr’14-Jun’14) Sales Rs.23.7 Bn - Growth registered in Base business profitability” issued by the Company

With reference to above, we wish to inform you that in the said press release, under the head ‘Key Financial Highlights’, inadvertently there was a typo error. The corresponding period for Consolidated sales should be read as “**Apr-Jun 2013**” instead of “Jan-Mar 2014”. Accordingly, the revised statement would be as under:

- **Consolidated Sales** were Rs.23.7 Bn [**Apr-Jun 2013**: Sales Rs.25.8 Bn].

We regret for the inconvenience caused.

Thanking you,

Yours faithfully,
For Ranbaxy Laboratories Limited

S.K. Patawari
Company Secretary